Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies

Cancer Causes and Control

Volumn 25, Issue 9, 2014, Pages 1083-1091

  Jacobs, Eric J ^a   Newton, Christina C ^a   Silverman, Debra T ^b   Nogueira, Leticia M ^b   Albanes, Demetrius ^b   Männistö, Satu ^c   Pollak, Michael ^d   Stolzenberg Solomon, Rachael Z ^b  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cohort study; Epidemiology; Pancreatic cancer; Serum transforming growth factor beta

Indexed keywords

BIOLOGICAL MARKER; TRANSFORMING GROWTH FACTOR BETA1;

AGED; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; FINLAND; HUMAN; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; STATISTICAL MODEL; UNITED STATES;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FINLAND; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TRANSFORMING GROWTH FACTOR BETA1; UNITED STATES;

EID: 84939880923     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0409-z     Document Type: Article

References (32)

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D et al (2013) Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105(3):175–201. doi:10.1093/jnci/djs491
2. Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, La Vecchia C (2013) Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol 24(10):2657–2671
3. Raimondi S, Maisonneuve P, Lowenfels AB (2009) Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6(12):699–708. doi:10.1038/nrgastro.2009.177
4. Lin Y, Kikuchi S, Tamakoshi A, Obata Y, Yagyu K, Inaba Y, Kurosawa M, Kawamura T, Motohashi Y, Ishibashi T (2006) Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case–control study. Cancer Causes Control 17:1077–1082
5. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S (2012) TGF-beta—an excellent servant but a bad master. J Transl Med 10:183. doi:10.1186/1479-5876-10-183
6. Truty MJ, Urrutia R (2007) Basics of TGF-beta and pancreatic cancer. Pancreatology 7(5–6):423–435. doi:10.1159/000108959
7. Hilbig A, Oettle H (2011) Transforming growth factor beta in pancreatic cancer. Curr Pharm Biotechnol 12(12):2158–2164
8. Yasuda M, Ito T, Oono T, Kawabe K, Kaku T, Igarashi H, Nakamura T, Takayanagi R (2008) Fractalkine and TGF-beta1 levels reflect the severity of chronic pancreatitis in humans. World J Gastroenterol 14:6488–6495
9. Adrych K, Smoczynski M, Stojek M, Sledzinski T, Korczynska J, Goyke E, Swierczynski J (2011) Coordinated increase in serum platelet-derived growth factor-BB and transforming growth factor-beta1 in patients with chronic pancreatitis. Pancreatology 11(4):434–440. doi:10.1159/000330294
10. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R (2010) Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24(3):349–358. doi:10.1016/j.bpg.2010.02.007
11. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM et al (2005) Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 592(1–2):147–154. doi:10.1016/j.mrfmmm.2005.06.013
12. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, Feigelson HS, Thun MJ (2002) The American cancer society cancer prevention study II nutrition cohort: rationale, study design, and baseline characteristics. Cancer 94(9):2490–2501. doi:10.1002/cncr.101970
13. The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 4(1):1–10
14. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J (2002) The Finnish Cancer Registry as follow-up source of a large trial cohort—accuracy and delay. Acta Oncol 41(4):381–388
15. Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, Virtamo J, Albanes D, Stolzenberg-Solomon RZ (2011) Serum C-reactive protein and risk of pancreatic cancer in two nested, case–control studies. Cancer Epidemiol Biomarkers Prev 20(2):359–369. doi:10.1158/1055-9965.EPI-10-1024
16. Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ, Vaught JB, Gail MH (2000) Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev 9(4):403–412
17. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RS, Pai LH, Denicoff AM, Noone MH, Cowan KH, O’Shaughnessy JA et al (1995) Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1(1):129–136
18. Grainger DJ, Mosedale DE, Metcalfe JC (2000) TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev 11(1–2):133–145
19. Kropf J, Schurek JO, Wollner A, Gressner AM (1997) Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison. Clin Chem 43(10):1965–1974
20. Bockman DE, Buchler M, Beger HG (1986) Ultrastructure of human acute pancreatitis. Int J Pancreatol 1(2):141–153. doi:10.1007/BF02788446
21. Luttenberger T, Schmid-Kotsas A, Menke A, Siech M, Beger H, Adler G, Grunert A, Bachem MG (2000) Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis. Lab Invest 80(1):47–55
22. Apte MV, Wilson JS (2012) Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J Gastroenterol Hepatol 27(Suppl 2):69–74. doi:10.1111/j.1440-1746.2011.07000.x
23. Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5):576–590. doi:10.1016/j.ccr.2011.09.009
24. Chen H, Lan X, Liu M, Zhou B, Wang B, Chen P (2013) Direct TGF-beta1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. Cell Biol Int 37(5):478–484. doi:10.1002/cbin.10067
25. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H (1999) Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 245(3):295–300
26. Grote VA, Kaaks R, Nieters A, Tjonneland A, Halkjaer J, Overvad K, Nielsen MRS, Boutron-Ruault MC, Clavel-Chapelon F, Racine A et al (2012) Inflammation marker and risk of pancreatic cancer: a nested case–control study within the EPIC cohort. Br J Cancer 106(11):1866–1874. doi:10.1038/bjc.2012.172
27. Bao Y, Giovannucci EL, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring JE et al (2013) Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five US cohorts. Cancer Epidemiol Biomarkers Prev 22(5):855–861. doi:10.1158/1055-9965.EPI-12-1458
28. Lin Y, Nakachi K, Ito Y, Kikuchi S, Tamakoshi A, Yagyu K, Watanabe Y, Inaba Y, Kazuo T (2009) Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults. Dis Markers 27(1):23–28. doi:10.3233/DMA-2009-0643
29. Koklu S, Coban S, Yuksel O, Arhan M (2007) Left-sided portal hypertension. Dig Dis Sci 52(5):1141–1149. doi:10.1007/s10620-006-9307-x
30. Peck-Radosavljevic M (2001) Hypersplenism. Eur J Gastroenterol Hepatol 13(4):317–323
31. Sanjo A, Satoi J, Ohnishi A, Maruno J, Fukata M, Suzuki N (2003) Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol 18(6):638–644
32. Akyuz F, Yekeler E, Kaymakoglu S, Horasanli S, Ibrisim D, Demir K, Aksoy N, Poturoglu S, Badur S, Okten A (2007) The role of thrombopoietin and spleen volume in thrombocytopenia of patients with noncirrhotic and cirrhotic portal hypertension. Turk J Gastroenterol 18(2):95–99